Nasdaq GlobeNewswire

The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement

Del

 

 

BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX) today announced an agreement to improve the development and accessibility of innovative research models and pre-clinical services to the global biomedical research community.

The agreement between Crown Bioscience, a global technology platform for Oncology, and Cardiovascular and Metabolic Disease, and JAX, a non-profit biomedical research institution and worldwide provider of high-quality research models and services, facilitates the shared objective of both organizations; to accelerate and advance the rate of pre-clinical research and discovery.

As part of the agreement: CrownBio will advance the use of JAX® Mice in client research studies. CrownBio will increase the utilization and improve access of JAX research models, including humanized NSG(TM) and NSG(TM)-SGM3, thus advancing the research and translational efforts of organizations globally.

JAX research scientists will have select access to CrownBio's pre-clinical contract laboratory services, providing JAX scientists with additional resources and facilities in which to continue the search for cures for cancer and other diseases.

"The agreement with JAX heralds a significant step forward for Oncology and Immuno-Oncology pre-clinical research," said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience.  "The utilization of JAX's scientific-leading humanized and translational models in combination with our PDX technology platforms will ensure the greatest potential for translatable drug development."

Research teams at JAX, focused on understanding the genetic and biochemical signatures that can be targeted by next-generation precision medicines, will immediately begin leveraging CrownBio's vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.

"The Jackson Laboratory's mission is to empower the global biomedical community in our shared quest to improve human health.  By harnessing our complementary strengths, this agreement allows us to propel scientific research and drug discovery globally by improving accessibility to the most advanced and highest quality pre-clinical research models and services," stated Auro Nair, Ph.D., President of JAX® Mice, Clinical & Research Services.  "Additionally, JAX research teams will be able to advance basic biological discoveries to therapies much more rapidly by utilizing the world's largest collection of PDX and cell-line models and services from CrownBio."

About Crown Bioscience

CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology and cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.

About The Jackson Laboratory

The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. It employs 1,900 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.

JAX Contact:
Dr. Charles Miller
Director of Marketing & Customer Support
207-288-6895 charles.miller@jax.org

Crown Bioscience Media Contact:
Gavin Cooper
Executive Director Marketing
marketing@crownbio.com
 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

DSM Sinochem Pharmaceuticals launches Atorvastatin film-coated tablets, expanding its finished dosage statins portfolio18.6.2018 11:23Pressemelding

Rijswijk, 18 June 2018, June 18, 2018 (GLOBE NEWSWIRE) -- Building upon its first generic finished dosage statin launch (Rosuvastatin) in January of this year, DSM Sinochem Pharmaceuticals (DSP) has this month released its fully backward-integrated, generic Atorvastatin drug product within the EU. Additional markets are scheduled to follow later in the year.Atorvastatin is used primarily in the prevention of cardiovascular disease and hyperlipidemia, commonly known as high cholesterol, the number one cause of death worldwide. Currently, statins are the most prescribed drug family globally in the fight against these potentially life-threatening conditions. Expanding statins portfolio With the launch now of Atorvastatin finished dosage formulation, coming on the heels of the successful launch of Rosuvastatin in January of 2018, DSP is actively expanding its statins drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. What sets DSP a

Juniper Networks Becomes Global Sponsor of World Robot Olympiad18.6.2018 11:00Pressemelding

Global competition that enables tens of thousands of young people to develop invaluable automation and programming skills now includes Engineering Simplicity award SUNNYVALE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE:JNPR), an industry leader in automated, scalable and secure networks, today announced that it has become the global technology partner of the World Robot Olympiad(TM) Association (WRO®), a non-profit organization that focuses on the hands-on development of robotics within STEM (Science, Technology, Engineering, Math) education on a worldwide scale. In a multi-year agreement, Juniper will work closely with WRO to promote, stage and further develop this global competition that attracts tens of thousands of young people. As part of its involvement in the competition, Juniper will be sponsoring a new trophy at this year's finals, WRO 2018, known as the Juniper Networks' Engineering Simplicity Honors Award. Juniper will judge teams in the Regular category

Skybox Security Continues Winning Streak with Multiple Awards and Honors18.6.2018 09:00Pressemelding

SAN JOSE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Skybox (TM) Security, a global leader in cybersecurity management, announced today it won Best Risk Management/Regulatory Compliance Solution at the 2018 SC Awards Europe in addition to the previous win in a similar category at the 2018 SC Awards US held in April. Skybox was also recognized as the "Highly Commended" finalist for Best Vulnerability Management Solution, Skybox(TM) Vulnerability Control, at the U.K. awards show in London on June 5, 2018. These honors add to the multiple awards given to the Skybox(TM) Security Suite, including several five-star reviews by SC Magazine in its Risk and Policy Management and Vulnerability and Threat Management group review categories. "We're delighted once again to be recognized for the hard work our dedicated engineers have put into making our platform a powerful, best-in-class technology. Our continuous innovations of the Suite help organizations keep up with the fast-changing nature of vul

IRIDEOS Acquires Enter18.6.2018 08:35Pressemelding

IRIDEOS Enhances Recent Strategic Acquisitions With Purchase of Leading Italian-Based Network and Cloud Services Provider MILAN, Italy, June 18, 2018 (GLOBE NEWSWIRE) -- IRIDEOS, the new Italian ICT provider for Businesses and Public Administration, announces today the acquisition of Enter, a leader in network and cloud services based in Italy. This purchase is the most recent of IRIDEOS acquisitions as the company works to consolidate the cloud and data center market throughout Italy. "With this new acquisition, our growth path continues, focused on strengthening our assets and skills in the Italian ICT space," says Mauro Maia, CEO of IRIDEOS. "A wider portfolio of services is now available for our customers, with new cloud solutions and international connectivity." As a leading ISP focused on providing global network connectivity, Enter's IP backbone spans 35+ Points of Presence (PoPs) worldwide, providing a wide range of network services, including Ethernet, VPN and cloud interconne

GlobeNewswire Test Release16.6.2018 07:00Pressemelding

LOS ANGELES, June 15, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539

INVNT/IP: US Responds to Nation-sponsored Crown-jewel Intellectual Property Theft15.6.2018 23:34Pressemelding

US Announcement of Large-Scale Tariffs in Response to Chinese Crown-Jewel Intellectual Property Theft Lauded by IP Protection Consortium INVNT/IP SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- The Trump administration today announced 25% tariffs on $50 billion in Chinese goods, representing the first time the United States government has marked sectors in US-China trade for retaliation as a response to theft of crown-jewel intellectual property. In a public statement, President Trump announced that the measures were targeted toward goods that "contain industrially significant technologies." US Trade Representative Robert Lighthizer applauded the move on Fox News, noting, "It's thorough. It's moderate. It's appropriate." In a further explanation of the move, he added, "What I want to do is make sure that we protect our technology here at home, that we stop cybertheft and forced technology transfer, and ultimately, remember: 'China 2025' is a $300 billion subsidy program. The United States h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom